Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease.

2.50
Hdl Handle:
http://hdl.handle.net/2336/30754
Title:
Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease.
Authors:
Vidarsson, Brynjar; Mosher, Deane F; Salamat, M Shahriar; Isaksson, Helgi J; Onundarson, Pall T
Citation:
Am. J. Hematol. 2002, 70(1):51-4
Issue Date:
1-May-2002
Abstract:
Fludarabine is becoming the initial therapy for low-grade lymphoproliferative malignancies, such as CLL and follicular lymphoma. Fludarabine is highly immunosuppressive in addition to being myelosuppressive and has been associated with neurotoxicity. Progressive multifocal leukoencephalopathy (PML) is an infection with JC virus of the white matter of the central nervous system seen mostly in immunosuppressed patients. We describe two patients treated with fludarabine who developed PML. Immunolabeling was positive for JCV in both patients, but PCR was repeatedly negative in one of them. We suggest that fludarabine may increase the risk of PML in patients with lymphoproliferative diseases.
Description:
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field
Additional Links:
http://dx.doi.org/10.1002/ajh.10085

Full metadata record

DC FieldValue Language
dc.contributor.authorVidarsson, Brynjar-
dc.contributor.authorMosher, Deane F-
dc.contributor.authorSalamat, M Shahriar-
dc.contributor.authorIsaksson, Helgi J-
dc.contributor.authorOnundarson, Pall T-
dc.date.accessioned2008-07-01T11:16:28Z-
dc.date.available2008-07-01T11:16:28Z-
dc.date.issued2002-05-01-
dc.date.submitted2008-07-01-
dc.identifier.citationAm. J. Hematol. 2002, 70(1):51-4en
dc.identifier.issn0361-8609-
dc.identifier.pmid11994982-
dc.identifier.doi10.1002/ajh.10085-
dc.identifier.urihttp://hdl.handle.net/2336/30754-
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractFludarabine is becoming the initial therapy for low-grade lymphoproliferative malignancies, such as CLL and follicular lymphoma. Fludarabine is highly immunosuppressive in addition to being myelosuppressive and has been associated with neurotoxicity. Progressive multifocal leukoencephalopathy (PML) is an infection with JC virus of the white matter of the central nervous system seen mostly in immunosuppressed patients. We describe two patients treated with fludarabine who developed PML. Immunolabeling was positive for JCV in both patients, but PCR was repeatedly negative in one of them. We suggest that fludarabine may increase the risk of PML in patients with lymphoproliferative diseases.en
dc.language.isoenen
dc.publisherWiley-Lissen
dc.relation.urlhttp://dx.doi.org/10.1002/ajh.10085en
dc.subject.meshAgeden
dc.subject.meshAntineoplastic Agentsen
dc.subject.meshHumansen
dc.subject.meshImmunosuppressive Agentsen
dc.subject.meshJC Virusen
dc.subject.meshLeukoencephalopathy, Progressive Multifocalen
dc.subject.meshLymphoproliferative Disordersen
dc.subject.meshMaleen
dc.subject.meshMiddle Ageden
dc.subject.meshVidarabineen
dc.titleProgressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease.en
dc.typeArticleen
dc.contributor.departmentDepartment of Hematology and Pathology, Landspitali University Hospital, Hringbraut, 101 Reykjavik, Iceland.en
dc.identifier.journalAmerican journal of hematologyen

Related articles on PubMed

All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.